Off-the-Shelf CAR NK Cell Therapy for Relapsed/Refractory AML and MDS

A clinical trial received more funding to continue developing an innovative treatment that enhances the immune system's power to kill cancer cells. This treatment is an off-the-shelf CAR-NK cell therapy called SENTI-202 by Senti Bio for people with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). 

Learn about SENTI-202 and how you may be eligible to receive it. 

What is the CAR-NK Cell Therapy SENTI-202? 

Natural killer (NK) cells are part of the immune system and can kill cancer cells. In people with AML and MDS, NK cells are often exhausted and have a difficult time finding and killing cancer cells on their own. 

To overcome this obstacle, researchers took NK cells from healthy adult donors and added a CAR protein (chimeric antigen receptor) to locate surface proteins specific to AML and MDS cells: CD33 and FLT3. 

The pre-clinical research for SENTI-202 showed that over 90% of cancer cells were killed with this treatment, leaving healthy cells alone. 

The promising results from this research opened the door to start a phase I clinical trial of SENTI-202 in which people with relapsed/refractory AML and MDS can receive the treatment. 

Another big advantage of SENTI-202 is that it is an off-the-shelf cell therapy. This means that they are ready to be used, and patients don’t need to wait multiple weeks for a CAR therapy to be made from their own immune system cells. 

Where Can I Receive SENTI-202? 

If you have relapsed/refractory AML or MDS, click here to review your eligibility to join the SENTI-202 study. To participate in the study, you don’t need to have both CD33 and FLT3 expressed on the surface of the cancer cells. Having either CD33+ or FLT3+ AML/MDS works. The majority of AML and MDS cells express CD33. About 25% of people with AML are FLT3+, and even fewer cases in MDS. 

The clinical trial has various recruiting locations in the United States and Australia. If you have questions about the study, please contact the principal investigator (PI) from the facility where you would like to receive the treatment.

Conclusion 

In summary, the CAR NK-cell therapy SENTI-202 by Senti Bio is available to people with relapsed/refractory AML and MDS through a recruiting clinical trial. We look forward to the progress of the study and its potential to help patients. 

Join HealthTree Cure Hub and Take Control of Your Care

We invite you to click the button below to create or log in to your free HealthTree Cure Hub account. There, you’ll have the ability to find clinical trials, track your labs, access side-effect solutions, and participate in research-accelerating surveys. 

Join / Sign HealthTree Cure Hub